Postmortem evaluation of end-organ toxicity in patients with glioblastoma (GBM) treated with temozolomide (TMZ) and bevacizumab (BEV).
J. Zhu
No relevant relationships to disclose
X. J. Tian
No relevant relationships to disclose
N. Linendoll
No relevant relationships to disclose
R. Pfannl
No relevant relationships to disclose
M. Pilichowska
No relevant relationships to disclose